0 CHECKOUT

Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review

  • ID: 1290947
  • August 2016
  • Region: Global
  • 69 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AIM Therapeutics Inc.
  • Endo International Plc
  • GTx, Inc.
  • Maruho Co., Ltd.
  • Mylan N.V.
  • Pfizer Canada Inc.
  • MORE

Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AIM Therapeutics Inc.
  • Endo International Plc
  • GTx, Inc.
  • Maruho Co., Ltd.
  • Mylan N.V.
  • Pfizer Canada Inc.
  • MORE

List of Tables

List of Figures

Section 1 - About the Company

Valeant Pharmaceuticals International, Inc. - Key Facts

Valeant Pharmaceuticals International, Inc. - Key Employees

Valeant Pharmaceuticals International, Inc. - Key Employee Biographies

Valeant Pharmaceuticals International, Inc. - Major Products and Services

Valeant Pharmaceuticals International, Inc. - Pharmaceutical Pipeline Products Data

Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area

Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase

Valeant Pharmaceuticals International, Inc. - History

Valeant Pharmaceuticals International, Inc. - Company Statement

Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 - Company Analysis

Valeant Pharmaceuticals International, Inc. - Business Description

Valeant Pharmaceuticals International, Inc. - Corporate Strategy

Valeant Pharmaceuticals International, Inc. - SWOT Analysis

SWOT Analysis - Overview

Valeant Pharmaceuticals International, Inc. - Strengths

Strength - Core Segment: Pharmaceuticals

Strength - Focus on Research & Development Activities

Strength - Business Partnerships

Valeant Pharmaceuticals International, Inc. - Weaknesses

Weakness - Patent Infringement Concerns

Weakness - Virazole - Microbial Contamination

Weakness - Higher Cost Structure

Valeant Pharmaceuticals International, Inc. - Opportunities

Opportunity - Global Dermatology Market

Opportunity - Product Pipeline

Opportunity - Inorganic Growth: Strategic Acquisitions

Valeant Pharmaceuticals International, Inc. - Threats

Threat - Intense Competition

Threat - Stringent Government Regulations

Threat - Reliance on Major Customers

Valeant Pharmaceuticals International, Inc. - Key Competitors

Section 3 - Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances

Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Valeant Pharmaceuticals International, Inc., Recent Deals Summary

Section 5 - Company’s Recent Developments

Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors

Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations

Jun 16, 2016: Valeant Pharmaceuticals Announces Launch Of New PreserVision AREDS 2 Formula + Multivitamin

Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director

Jun 07, 2016: Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results

May 26, 2016: Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller

May 16, 2016: Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel

May 16, 2016: Valeant Pharmaceuticals Provides Update on Regulatory Matters

May 16, 2016: Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters

May 05, 2016: Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs

Section 6 - Appendix

Methodology

Ratio Definitions

About

Contact Us

Disclaimer

List of Tables

Valeant Pharmaceuticals International, Inc., Key Facts

Valeant Pharmaceuticals International, Inc., Key Employees

Valeant Pharmaceuticals International, Inc., Key Employee Biographies

Valeant Pharmaceuticals International, Inc., Major Products and Services

Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Therapy Area

Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Development Stage

Valeant Pharmaceuticals International, Inc., Pipeline Products By Therapy Area and Development Phase

Valeant Pharmaceuticals International, Inc., History

Valeant Pharmaceuticals International, Inc., Other Locations

Valeant Pharmaceuticals International, Inc., Subsidiaries

Valeant Pharmaceuticals International, Inc., Key Competitors

Valeant Pharmaceuticals International, Inc., Ratios based on current share price

Valeant Pharmaceuticals International, Inc., Annual Ratios

Valeant Pharmaceuticals International, Inc., Interim Ratios

Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Valeant Pharmaceuticals International, Inc., Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area

Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase

Valeant Pharmaceuticals International, Inc., Performance Chart (2011 - 2015)

Valeant Pharmaceuticals International, Inc., Ratio Charts

Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD

Note: Product cover images may vary from those shown
3 of 4

Xenon Pharmaceuticals Inc.
Stratus Pharmaceuticals, Inc.
Sirona Biochem Corp
Polydex Pharmaceuticals Limited
Pfizer Canada Inc.
Opiant Pharmaceuticals, Inc.
Mylan N.V.
Maruho Co., Ltd.
GTx, Inc.
Endo International Plc
AIM Therapeutics Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.